Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CASR | P41180 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | LTC4S | Q16873 | 2/20 | 0.48 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1253481 | 1.00 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP2C9CYP2C19CASR | |
| SCHEMBL1252229 | 1.00 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP2C9CYP2C19CASR | |
| SCHEMBL31085545 | 1.00 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP2C9CYP2C19CASR | |
| SCHEMBL12871845 | 0.85 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19CASR | |
| SCHEMBL15540540 | 0.85 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19CASR | |
| SCHEMBL19286310 | 0.83 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP2C9CYP2C19CASR | |
| SCHEMBL1331699 | 0.83 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP2C9CYP2C19CASR | |
| Hydrochloric Acid SCHEMBL607851 | 0.83 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP2C9CYP2C19CASR | |
| SCHEMBL25453200 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19CASR | |
| SCHEMBL29254110 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109336887-B | Benzimidazole chiral heterocyclic compound and preparation method and application thereof | 中山大学 | 2021-12-17 | — | — | CN | claimed |
| EP-0044158-A1 | Novel optically active imidazolidin-2-one derivatives and their production | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1982-01-20 | — | — | EP | claimed |
| WO-2024137764-A1 | NOVEL COVALENT INHIBITORS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| WO-2023114379-A1 | PLPRO INHIBITORS | HUAHAI US INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| CN-110862324-B | Direct synthesis method of chiral secondary amine compound | 西北农林科技大学 | 2023-01-31 | — | — | CN | disclosed |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| EP-3177612-B1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION AS (DK) | 2022-02-23 | — | — | EP | disclosed |
| US-11254681-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | NUEVOLUTION A/S (DK) | 2022-02-22 | — | — | US | disclosed |
| CN-109336887-B | Benzimidazole chiral heterocyclic compound and preparation method and application thereof | 中山大学 | 2021-12-17 | — | — | CN | disclosed |
| US-11160803-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2021-11-02 | — | — | US | disclosed |
| US-5106866-A | Skin disorders | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1992-04-21 | — | — | US | disclosed |
| US-5089046-A | Herbicides or miticide | SANDOZ LTD. (CH) | 1992-02-18 | — | — | US | disclosed |
| US-5021458-A | Amine derivatives and fungicides containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1991-06-04 | — | — | US | disclosed |
| EP-0164697-B1 | AMINE DERIVATIVES, PROCESSES FOR PREPARING THE SAME AND FUNGICIDES CONTAINING THE SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 1990-11-07 | — | — | EP | disclosed |
| US-4871735-A | HYPOTENSIVE, ANTIISCHEMIC AGENTS | DR. KARL THOMAE GMBH | 1989-10-03 | — | — | US | disclosed |
| EP-0164697-A2 | Amine derivatives, processes for preparing the same and fungicides containing the same | Kaken Pharmaceutical Co., Ltd. (JP) | 1985-12-18 | — | — | EP | disclosed |
| EP-0044158-B1 | NOVEL OPTICALLY ACTIVE IMIDAZOLIDIN-2-ONE DERIVATIVES AND THEIR PRODUCTION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-08-15 | — | — | EP | disclosed |
| US-4403096-A | Optically active imidazolidin-2-one derivatives | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-09-06 | — | — | US | disclosed |
| EP-0044158-A1 | Novel optically active imidazolidin-2-one derivatives and their production | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1982-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254681-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | PPARD, PPARG, RORC | ALDH1A1 1245/4885CYP1A2 734/4885CYP2C9 848/4885 |
| US-11160803-B2 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | ALDH1A1 1678/4885CYP1A2 542/4885CYP2C9 1357/4885 |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | ALDH1A1 1311/4885CYP1A2 4381/4885CYP2C9 3706/4885 |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | ALDH1A1 1599/4885CYP1A2 548/4885CYP2C9 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.